Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08EOW
|
|||
| Drug Name |
RG7112
|
|||
| Synonyms |
RO5045337; QBGKPEROWUKSBK-QPPIDDCLSA-N; 939981-39-2; UNII-Q8MI0X869M; Q8MI0X869M; RO-5045337; CHEMBL2386346; Ro 5045337; GTPL9599; SCHEMBL12704861; DTXSID60240182; MolPort-044-560-282; EX-A1686; s7030; ZINC96270381; BDBM50434287; AKOS027282701; CS-0330; HY-10959; RG7112 (RO5045337); [(4s,5r)-2-(4-t-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]
Click to Show/Hide
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [2] | ||
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C38H48Cl2N4O4S
|
|||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)C(C)(C)C)C2=NC(C(N2C(=O)N3CCN(CC3)CCCS(=O)(=O)C)(C)C4=CC=C(C=C4)Cl)(C)C5=CC=C(C=C5)Cl
|
|||
| InChI |
1S/C38H48Cl2N4O4S/c1-8-48-33-26-29(36(2,3)4)14-19-32(33)34-41-37(5,27-10-15-30(39)16-11-27)38(6,28-12-17-31(40)18-13-28)44(34)35(45)43-23-21-42(22-24-43)20-9-25-49(7,46)47/h10-19,26H,8-9,20-25H2,1-7H3/t37-,38+/m0/s1
|
|||
| InChIKey |
QBGKPEROWUKSBK-QPPIDDCLSA-N
|
|||
| CAS Number |
CAS 939981-39-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00559533) A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.